Charles River Laboratories International, Inc.’s stock price dips to $198.55, marking a 2.43% decrease

Charles River Laboratories International, Inc. (CRL)

198.55 USD -4.94 (-2.43%) Volume: 0.73M

Charles River Laboratories International, Inc.’s stock price stands at 198.55 USD, marking a trading session decline of -2.43% on a volume of 0.73M, and reflecting a YTD performance drop of -16.01%, underlining the volatility of CRL’s stock performance in the market.

Latest developments on Charles River Laboratories International, Inc.

Recent events have had a significant impact on Charles River Laboratories International, Inc. (NYSE:CRL) stock price movements. Sequoia Financial Advisors LLC disclosed a $2.94 million position in the company, while Cwm LLC revealed $431,000 stock holdings. Charles River Labs EVP also sold $354,860 in company stock. Mizuho Securities cut the shares target, but retained a neutral rating. Additionally, William Blair issued a Q1 2025 earnings forecast for the company. These developments have drawn attention to Charles River’s revenue trends, making it a stock to watch in the coming days.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Charles River Laboratories International, Inc. is expected to have a mixed long-term outlook based on the Smartkarma Smart Scores. While the company scores well in areas such as value and growth, its resilience and dividend scores are lower. This indicates that Charles River Laboratories may face some challenges in terms of withstanding economic downturns and providing consistent dividend payouts to investors.

Overall, Charles River Laboratories provides research tools and support services for drug discovery and development, catering to a wide range of customers in the pharmaceutical and biotechnology industries. With a focus on animal research models, the company plays a crucial role in the development of new drugs, devices, and therapies. Despite some areas of concern, Charles River Laboratories‘ momentum score suggests that the company is on a positive trajectory for future growth and success.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma